Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Febuxostat

Nature Reviews Drug Discovery volume 8, pages 191–192 (2009)Cite this article

Abstract

In May 2008, febuxostat (Adenuric; Ipsen), an inhibitor of xanthine oxidase, was granted marketing authorization by the European Commission for the treatment of chronic hyperuricaemia in conditions in which urate deposition has occurred, such as gouty arthritis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Xanthine oxidase inhibitors.

References

  1. Choi, H. K. et al. Pathogenesis of gout. Ann. Intern. Med. 143, 499–516 (2005).

    Article  CAS  PubMed  Google Scholar 

  2. Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312–1324 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Pascual, E. & Sivera, F. Therapeutic advances in gout. Curr. Opin. Rheumatol. 19, 122–127 (2007).

    Article  PubMed  Google Scholar 

  4. Okamoto, K. et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J. Biol. Chem. 278, 1848–1855 (2003).

    Article  CAS  PubMed  Google Scholar 

  5. Osada, Y. et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur. J. Pharmacol. 241, 183–188 (1993).

    Article  CAS  PubMed  Google Scholar 

  6. Komoriya, K. et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur. J. Pharmacol. 250, 455–460 (1993).

    Article  CAS  PubMed  Google Scholar 

  7. European Medicines Agency (EMEA). European Public Assessment Report – Adenuric. EMEA web site [online], (2008).

  8. Schumacher, H. R. Jr et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59, 1540–1548 (2008).

    Article  CAS  PubMed  Google Scholar 

  9. Becker, M. A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450–2461 (2005).

    Article  CAS  PubMed  Google Scholar 

  10. Pascual, E. & Sivera, F. The time required for disappearance of urate crystals from synovial fluid after successful hypouricemic treatment relates to the duration of gout. Ann. Rheum. Dis. 66, 1056–1058 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Perez-Ruiz, F. et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 47, 356–360 (2002).

    Article  CAS  PubMed  Google Scholar 

  12. Singh, J. et al. Quality of care for gout in the US needs improvement. Arthritis Rheum. 57, 822–829 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Mikuls, T. et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology 44, 1038–1042 (2005).

    Article  CAS  PubMed  Google Scholar 

  14. Reinders, M. K. et al. A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann. Rheum. Dis. 16 Jul 2008 (doi:10.1136/ard.2008.091462).

    Article  PubMed  Google Scholar 

  15. IMS MIDAS (2007).

  16. Febuxostat for the management of hyperuricaemia in patients with gout. National Institute for Health and Clinical Excellence web site [online], (2008).

  17. Hauber, A. Bear Sterns Equity Research Report (Bear Sterns, 22 Feb 2008).

Download references

Author information

Authors and Affiliations

  1. Eliseo Pascual and Francisca Sivera are at Hospital General Universitario de Alicante, Universidad Miguel Hernández, Alicante, Spain.,

    Eliseo Pascual & Francisca Sivera

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK.,

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. pascual_eli@gva.es; UYasothan@de.imshealth.com; p.kirkpatrick@nature.com,

    Peter Kirkpatrick

  4. UYasothan@de.imshealth.com,

    Peter Kirkpatrick

Authors
  1. Eliseo Pascual
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisca Sivera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

E.P. has given a presentation on gout diagnosis at a symposium on febuxostat organized by Ipsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pascual, E., Sivera, F., Yasothan, U. et al. Febuxostat. Nat Rev Drug Discov 8, 191–192 (2009). https://doi.org/10.1038/nrd2831

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2831

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing